Allogene Therapeutics (ALLO) Operating Expenses (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Operating Expenses data on file, last reported at $46.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 29.3% year-over-year to $46.1 million; the trailing twelve-month figure through Mar 2026 stood at $190.2 million (down 29.26% YoY), and the FY2025 full-year result was $209.3 million, down 23.39% from the prior year.
• Operating Expenses grew to $46.1 million in Q1 2026, from $42.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $99.1 million in Q1 2023 to a low of $42.4 million in Q4 2025.
• A 5-year average of $70.1 million and a median of $71.4 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 30.4% in 2022 and tumbled 37.44% in 2025, its largest moves.
• Tracing ALLO's Operating Expenses over 5 years: stood at $96.4 million in 2022, then dropped by 11.71% to $85.1 million in 2023, then slipped by 28.94% to $60.5 million in 2024, then dropped by 29.9% to $42.4 million in 2025, then climbed by 8.7% to $46.1 million in 2026.
• Business Quant data shows ALLO's Operating Expenses at $46.1 million in Q1 2026, $42.4 million in Q4 2025, and $44.9 million in Q3 2025.